Received Mar 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Z005055 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No additional AE; Nurse called and reported inadvertent administration of expired GARDASIL 9 to a 61-year-old patient. Nurse stated that this was the patient's second dose of GARDASIL 9 that was administered on 03MAR2026 with an expiration date of 27FEB2026.; Nurse called and reported inadvertent administration of expired GARDASIL 9 to a 61-year-old patient. Nurse stated that this was the patient's second dose of GARDASIL 9 that was administered on 03MAR2026 with an expiration date of 27FEB2026.; This spontaneous report was received from a nurse and refers to a 61-year-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, previous drugs reactions and allergies were not reported. On an unknown date, the patient was vaccinated with the first dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) administered as prophylaxis (Lot No., expiration date, strength, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). On 03-Mar-2026, the patient was inadvertently vaccinated with an expired second dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) administered as prophylaxis (Lot No. Z005055 has been verified to be a valid lot number for [human papillomavirus 9-valent vaccine, recombinant], expiration date reported and upon internal validation established as 27-Feb-2026) (strength, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided) (expired product administered)(product administered to patient of inappropriate age). No additional adverse event was reported (no adverse event).